Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment
Authors:
- Ninel Z. GregoriNGNinel Z. Gregori
- Harry W. FlynnHFHarry W. Flynn
- Stephen G. SchwartzSSStephen G. Schwartz
- Philip J. RosenfeldPRPhilip J. Rosenfeld
- Kamyar VaziriKVKamyar Vaziri
- Andrew A. MoshfeghiAMAndrew A. Moshfeghi
- Jorge A. FortunJFJorge A. Fortun
- Jaclyn L. KovachJKJaclyn L. Kovach
- Sander R. DubovySDSander R. Dubovy
- Thomas A. AlbiniTAThomas A. Albini
- Janet L. DavisJDJanet L. Davis
- Audina M. BerrocalABAudina M. Berrocal
- 1 June 2015
- journal article
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 46 (6) , 643-648
Abstract
BACKGROUND AND OBJECTIVE: To assess the incidence and outcomes of infectious endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents. PATIENTS AND METHODS: Patient records at the Bascom Palmer Eye Institute (BPEI) from January 1, 2005, through December 31, 2014, were reviewed. The largest commercial claims and encounters database in the U.S. (MarketScan) was utilized to calculate the population-based endophthalmitis rate for 2011 to 2013. RESULTS: The population-based rate of endophthalmitis after anti-VEGF injections for 2011 to 2013 was 391/740,757 (0.053%). BPEI’s rate was 20/121,285 (0.016%) during the study period: eight after bevacizumab (0.012%), six after ranibizumab (0.018%), and six after aflibercept (0.031%) injection. Nine BPEI cases (45%) were culture-positive: Streptococcus species (5), coagulase-negative Staphylococcus (3), and non-anthracis Bacillus (1). Final visual acuity varied from 20/25 to no light perception. CONCLUSION: Endophthalmitis after anti-VEGF injection was uncommon in our institution and in the population-based database. Treatment outcomes were variable but generally fared better in the culture-negative cases. [ Ophthalmic Surg Lasers Imaging Retina . 2015;46:643–648.]Keywords
This publication has 16 references indexed in Scilit:
- Noninfectious Inflammation After Intravitreal Injection of Aflibercept: Clinical Characteristics and Visual OutcomesAmerican Journal of Ophthalmology, 2014
- Meta-Analysis of Infectious Endophthalmitis After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor AgentsOphthalmic Surgery, Lasers and Imaging Retina, 2014
- Vitreous Inflammation Associated with Intravitreal Anti-VEGF PharmacotherapyMediators of Inflammation, 2013
- Aflibercept-Related Sterile InflammationOphthalmology, 2013
- Update on Risk of Endophthalmitis After Intravitreal Drug Injections and Potential Impact of Elimination of Topical AntibioticsArchives of Ophthalmology (1950), 2012
- Uveitis Following Intravitreal Bevacizumab: A Non-Infectious ClusterOphthalmic Surgery, Lasers and Imaging Retina, 2011
- Endophthalmitis Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Neovascular Age-Related Macular DegenerationSeminars in Ophthalmology, 2011
- ENDOPHTHALMITIS AFTER INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTAGONISTSRetina, 2011
- META-ANALYSIS OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTSRetina, 2011
- Endogenous endophthalmitis: 10-year experience at a tertiary referral centreEye, 2010